Multimeric Biotherapeutics, Inc. is developing FortiVac™ as a vaccine platform for extraordinarily strong CD8+ T cell responses – a critical unmet need in vaccinology.
FortiVac uses CD40 ligand (CD40L) to activate dendritic cells and simultaneously pulse them with antigen. This is done using a patented fusion protein of CD40L, antigen, and a multimerization scaffold taken from surfactant protein D (SPD) = FortiVac. The result is an extraordinary activation of CD8+ “killer” T cell responses.
FortiVac is being developed for two unmet medical needs: vaccines to treat cancer and to prevent serious infections.